Floatz logo

Eplerenone

Insulin Resistance

Maastricht University Medical CenterSmall moleculePhase 4 / ApprovedDormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
81/ 100

Competitive context

7 Active assets in the Insulin Resistance cohort.

Asset / SponsorPhaseRating
Semaglutide
University Hospital Tuebingen
Phase 4BB
CITALOPRAM
Massachusetts General Hospital
Phase 4BB
Sertraline
Massachusetts General Hospital
Phase 4BB
ADVICOR COMPONENT NIACIN
Baylor College of Medicine
Phase 4BB
TAMOXIFEN
Veterans Medical Research Foundation
Phase 4BB

View all 32 →

Same molecule, other indications

Eplerenone is also rated in:

abdominal obesity-metabolic syndromeDormant
B
Indicative ·
62 / 100
View asset →
hypertensive disorderDormant
B
Indicative ·
61 / 100
View asset →
metabolic syndrome XDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →